financetom
Business
financetom
/
Business
/
Expect to repay debt of Rs 26 crore, says IOL Chemicals
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Expect to repay debt of Rs 26 crore, says IOL Chemicals
May 18, 2018 7:54 AM

We expect to repay the debt of Rs 26 crore, said Vijay Garg, joint Managing Director, IOL Chemicals and Pharmaceuticals.

"Around Rs 26 crore is our repayment which is scheduled for this year. So debt will definitely not increase," said Garg to CNBC-TV18.

IOL Chemicals and Pharmaceuticals is in focus after reporting a strong set of numbers this quarter.

Garg said the company next year will be adding few quantities in the chemical and pharmaceutical segment and we are confident that we will be able to add another 30%.

“This year, we have done 29.46% in topline. Next year, it will be around 30-40%,” he added.

He further said that bottomline will increase this year as we will be signing new contracts with all our customers to whom we have supplied material last year.

First Published:May 18, 2018 4:54 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Natixis and Generali in early talks for asset management tie-up, FT reports
Natixis and Generali in early talks for asset management tie-up, FT reports
Nov 25, 2024
Nov 25 (Reuters) - France's Natixis Investment Managers is holding early-stage talks with Italian insurer Generali about a potential tie-up, the Financial Times reported on Monday. The firms have not yet agreed to terms of a deal, and it remains uncertain whether the talks will lead to an agreement, the report added, citing sources. A spokesperson for BPCE, the parent...
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Nov 25, 2024
Cassava Sciences Inc. stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints. In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam...
KULR Gets US Navy Contract to Develop Technology for Battery Safety
KULR Gets US Navy Contract to Develop Technology for Battery Safety
Nov 25, 2024
09:28 AM EST, 11/25/2024 (MT Newswires) -- KULR Technology ( KULR ) said Monday it has been awarded a contract by the US Navy to develop high-temperature internal short circuit cells for improved battery safety in critical applications. The project will support a wide range of uses, particularly in the aviation sector, by allowing the simulation of extreme conditions to...
MicroStrategy Provides Update on Bitcoin Holdings
MicroStrategy Provides Update on Bitcoin Holdings
Nov 25, 2024
09:21 AM EST, 11/25/2024 (MT Newswires) -- MicroStrategy ( MSTR ) said Monday that it purchased 55,500 bitcoins for $5.4 billion in cash, at an average price of $97,862 per bitcoin between Nov. 18 and Nov. 24. As of Nov. 24, MicroStrategy ( MSTR ) owned 386,700 bitcoins, with a total purchase price of $21.9 billion and an average price...
Copyright 2023-2025 - www.financetom.com All Rights Reserved